Comparison of Uterine and Extrauterine Leiomyosarcoma: Molecular Profiles Insight
Leiomyosarcoma (LMS) is a rare and aggressive type of soft tissue cancer that develops from smooth muscle cells. Historically, uterine and extrauterine LMS were considered identical due to their structural similarities, but they are now recognized as distinct diseases.
Diagnosis primarily involves histological examination of biopsy specimens to identify spindle-shaped tumour cells with pleomorphism, necrosis, and high mitotic activity typical of LMS. Immunohistochemical staining is crucial to confirm diagnosis and differentiate from other tumours, with positive markers including smooth muscle actin (SMA), desmin, and h-caldesmone confirming smooth muscle origin.
For uterine LMS, molecular profiling may highlight mutations and biomarkers like PD-L1 expression, which can influence therapeutic decisions such as immune checkpoint inhibitor use. Uterine LMS tends to have a more aggressive clinical course with distinct molecular alterations, including potential responsiveness to immunotherapy when high PD-L1 expression is present.
Extrauterine LMS (e.g., breast or vaginal origin) may differ in growth kinetics and metastatic patterns (commonly lungs, liver, brain), but shares the fundamental smooth muscle differentiation. Due to rarity, localized extrauterine LMS diagnostic criteria and treatment regimens are often extrapolated from uterine or soft tissue LMS.
Surgical excision with clear margins remains cornerstone for both uterine and extrauterine LMS. Adjuvant chemotherapy is considered for high-risk or advanced cases, but its impact on overall survival is uncertain. Molecular profiling helps tailor therapies, especially immunotherapy in uterine LMS with biomarkers like PD-L1.
The rarity of extrauterine LMS limits standardized protocols, often requiring individualized multidisciplinary approaches extrapolated from uterine LMS and soft tissue sarcomas. Differences in molecular pathogenesis between Uterine and Extrauterine LMS include more damaged genes involved in hormone signalling for Uterine LMS, and more mutations in genes that control cell metabolism and energy production for Extrauterine LMS.
These molecular differences can lead to differences in treatment response, with some chemotherapy drugs being effective for one person but not for another. Epigenetic modifications, such as DNA methylation patterns and histone modifications, can be seen in both types of LMS. Uterine LMS express hormone receptors for oestrogen and progesterone, while extrauterine LMS rarely do.
LMS can occur either within the uterus (Uterine LMS) or outside the uterus (Extrauterine LMS). Growth factor dependencies differ between uterine and extrauterine LMS. Uterine LMS tend to spread to the lungs first, while extrauterine tumours spread to multiple areas simultaneously and follow a different pattern.
Extrauterine LMS presents with symptoms depending on their location, such as abdominal tumours growing silently, blood vessel tumours causing arm or leg swelling and bleeding, and limb tumours appearing as painless lumps. Several biomarkers are available for use in the clinical setting to distinguish between uterine and extrauterine LMS, including hormone receptor testing, IGF1R, PARP1 protein, mTOR pathway proteins, and metabolic protein differences.
The breakthrough in understanding the differences between Uterine and Extrauterine LMS was made possible by genetic sequencing technology. Under a microscope, LMS tissues have similar distinctive features, but their molecular differences can be examined through DNA analysis, protein production, and gene regulation.
- The diagnostic process for Leiomyosarcoma (LMS) often involves histological examination, and immunohistochemical staining to confirm smooth muscle origin, such as identifying positive markers like smooth muscle actin (SMA), desmin, and h-caldesmone.
- Uterine LMS can have a distinct molecular makeup compared to extrauterine LMS, with more damaged genes involved in hormone signaling, while extrauterine LMS shows more mutations in genes that control cell metabolism and energy production.
- Surgical excision with clear margins is the cornerstone for both uterine and extrauterine LMS, but adjuvant chemotherapy is typically considered for high-risk or advanced cases, whose impact on overall survival may vary.
- Biomarkers, such as hormone receptor testing, IGF1R, PARP1 protein, mTOR pathway proteins, and metabolic protein differences, can help distinguish between uterine and extrauterine LMS in the clinical setting, contributing to personalized health-and-wellness and womens-health treatments.
